We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder (MATRIX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00224146
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : November 30, 2011
Information provided by (Responsible Party):
Watson Pharmaceuticals

Brief Summary:
This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)

Condition or disease Intervention/treatment Phase
Overactive Bladder Urinary Incontinence Quality of Life Drug: oxybutynin transdermal delivery system (Oxytrol(r)) Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2878 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)
Study Start Date : May 2004
Actual Primary Completion Date : May 2005
Actual Study Completion Date : May 2005

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Change in health-related quality of life

Secondary Outcome Measures :
  1. Change in other outcomes such as:
  2. depression
  3. work productivity
  4. participant satisfaction
  5. effect of enhanced patient education on any of the above outcomes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency

Exclusion Criteria:

  • Patients for whom Oxytrol(r) is contraindicated.
  • Patients treated with Oxytrol(r) prior to participation in this study.
  • Patients residing in long-term care facilities or nursing homes.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00224146

Layout table for location information
United States, Alabama
Mobile, Alabama, United States
United States, Arizona
Tucson, Arizona, United States
United States, California
Torrance, California, United States
United States, Connecticut
Rocky Hill, Connecticut, United States
United States, Georgia
Valdosta, Georgia, United States
United States, Louisiana
Gretna, Louisiana, United States
United States, Michigan
Bloomfield Hills, Michigan, United States
United States, New York
Poughkeepsie, New York, United States
United States, North Carolina
Winston-Salem, North Carolina, United States
United States, Texas
Tomball, Texas, United States
Sponsors and Collaborators
Watson Pharmaceuticals
Layout table for investigator information
Study Director: Naomi V. Dahl, PharmD Watson Laboratories, Inc.
Publications of Results:
Layout table for additonal information
Responsible Party: Watson Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00224146    
Other Study ID Numbers: OXY0402
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: November 30, 2011
Last Verified: November 2011
Keywords provided by Watson Pharmaceuticals:
transdermal oxybutynin
overactive bladder
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Incontinence
Urinary Bladder, Overactive
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Urinary Bladder Diseases
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Urological Agents